119 related articles for article (PubMed ID: 35188013)
1. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol.
Khan MA; Singh D; Fatma H; Akhtar K; Arjmand F; Maurya S; Siddique HR
Drug Chem Toxicol; 2023 Mar; 46(2):380-391. PubMed ID: 35188013
[TBL] [Abstract][Full Text] [Related]
2. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract][Full Text] [Related]
3. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
4. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
5. Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells.
Saleem M; Murtaza I; Witkowsky O; Kohl AM; Maddodi N
Biochem Biophys Res Commun; 2009 Oct; 388(3):576-82. PubMed ID: 19683515
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
7. Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.
Maurya SK; Fatma H; Maurya AK; Mishra N; Siddique HR
In Silico Pharmacol; 2022; 10(1):16. PubMed ID: 36072559
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
9. Role of Testosterone Levels on the Combinatorial Effect of
Pillai P; Pooleri GK; Nair SV
Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860
[TBL] [Abstract][Full Text] [Related]
10. Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
Maxwell PJ; McKechnie M; Armstrong CW; Manley JM; Ong CW; Worthington J; Mills IG; Longley DB; Quigley JP; Zoubeidi A; de Bono JS; Deryugina E; LaBonte MJ; Waugh DJJ
Mol Cancer Res; 2022 Jun; 20(6):841-853. PubMed ID: 35302608
[TBL] [Abstract][Full Text] [Related]
11. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
12. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
13. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
14. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
16. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Nadiminty N; Tummala R; Liu C; Yang J; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2013 Aug; 12(8):1629-37. PubMed ID: 23699654
[TBL] [Abstract][Full Text] [Related]
17. An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.
Ushijima M; Shiota M; Matsumoto T; Kashiwagi E; Inokuchi J; Eto M
Cancer Sci; 2022 May; 113(5):1731-1738. PubMed ID: 35118769
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
